|Description||The (S)- but not (R)-isomers of willardiine and 5-bromowillardiine were potent agonists, producing rapidly but incompletely desensitizing responses. At a concentration of 1.8 mM, Ca2+ inhibited the currents induced by 100 microM willardiine by approximately 50%. In newborn mice (P5, histopathology at P10), local injection of the AMPA receptor agonist S-bromo-willardiine at day 5 after birth induced cortical damage and white matter damage, which was reduced in a dose-dependent manner by the AMPA receptor antagonists.|
CMPDA is a positive allosteric modulator of AMPA receptors. Binds at the modulator binding pocket located at the interdimer interface and the clamshell hinges.
Aniracetam is a nootropics and neuroprotective drug.
LY 404187 is an allosteric modulator of AMPA receptors (IC50 = 0.15μM, 0.21μM, 1.66μM and 5.65 μM for GluA2i, GluA4i, GluA3i and GluA1i, respectively).
A poliamine amide as potent Spermidine uptake inhibitor.
A caged version of (S)-AMPA. (S)-AMPA is an AMPA receptor agonist.
Noopept is a nootropic and neuroprotective drug that normalizes the balance of the pro- and antioxidant systems. Noopept modulates a variety of physiological fu...
The hydrobromide salt form of (RS)-AMPA, which has been found to be an agonist of the excitatory neurotransmitter L-glutamic Acid.
It is one of a series of AMPA modulators for the potential treatment of Alzheimer's disease, schizophrenia, and mild cognitive impairment (MCI). An ampakine dru...